ArticleJournal of clinical medicine research2016
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Takashi Iizuka et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.